News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

February 22, 2018 Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy
January 2, 2018 Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
December 20, 2017 Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
December 19, 2017 Apellis Pharmaceuticals Expands Management Team, Appoints Timothy Sullivan Chief Financial Officer
December 8, 2017 Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)
November 13, 2017 Apellis Pharmaceuticals Announces Closing of its Initial Public Offering
November 8, 2017 Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
August 24, 2017 Apellis Pharmaceuticals Announces that APL-2 Met its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
August 10, 2017 Apellis Pharmaceuticals Announces $60 Million Series E Financing
June 29, 2017 Apellis Pharmaceuticals Announces Positive Data from APL-2 Studies Showing Rapid and Durable Improvements in LDH and Hemoglobin Levels in PNH